Pneumokokkenimpfung bei Erwachsenen – Hintergründe der aktuellen Diskussion

Schlüsselwörter

Pneumokokkenimpfung - Konjugatvakzine

Keywords

pneumococcal vaccination - conjugate vaccine

• Literatur

• 1 Bogaert D et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004; 363: 1871-1872
• 2 Dagan R et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174: 1271-1278
• 3 de Roux A et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults. Clin Infect Dis 2008; 46: 1015-1023
• 4 French N et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362: 812-822
• 5 Hak E et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66: 378-383
• 6 Huss A et al. Efficacy of pneumococcal vaccination in adults. CMAJ 2009; 180: 48-58
• 7 Jackson L et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. London: European Conference on Clinical Microbiology and Infectious Diseases (ECCMID); 2011
• 8 Jackson L et al. 13-valent Pneumococcal Conjugate Vaccine (PCV13) Enhances the Response to Subsequent PCV13 and 23-valent Pneumococcal Polysaccharide (PPSV23) Vaccinations in Adults 50 Years and Older. Boston: Annual Meeting of the Infectious Diseases Society of America (IDSA); 2011
• 9 Kuhlmann A et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Economics Rev 2012; 2: 4
• 10 Kwetkat A, Hagel S, Pletz MW. Impfungen im Alter. Der Pneumologe 2012; 9: 1-7
• 11 Maruyama T et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents. BMJ 2010; 340: c1004
• 12 Moberley SA et al. Vaccines for preventing pneumococcal infection in adults. . Cochrane Database Syst Rev 2008; CD000422
• 13 Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?. Clin Infect Dis 2011; 52: 633-640
• 14 O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. Lancet Infect Dis 2007; 7: 597-606
• 15 Pilishvili T et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41
• 16 Pletz MW et al. Pneumokokkenimpfung: Konjugatimpfstoff induziert Herdenimmunitat und reduziert Antibiotikaresistenz. Dtsch Med Wochenschr 2008; 133: 358-362
• 17 Pletz MW et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2004; 48: 3491-3497
• 18 Pletz MW et al. Epidemiologie und Erreger bei ambulant erworbener Pneumonie (CAP). Dtsch Med Wochenschr 2011; 136: 775-780
• 19 Pletz MW et al. The burden of pneumococcal pneumonia. Experience of the German Competence Network CAPNETZ. Pneumologie 2012; 66: 470-475
• 20 Pletz MW et al. Impfungen. Dtsch Med Wochenschr 2011; 136: 2011-2015
• 21 Rudolf D et al. International pneumococcal clones equal or exceed the fitness of other strains despite the accumulation of antibiotic resistance. Antimicrob Agents Chemother 2011; 55: 4915-4917
• 22 Stephens DS et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine. Lancet 2005; 365: 855-863
• 23 STIKO. Stellungnahme zur Impfung Erwachsener gegen Pneumokokken. Epidemiol Bull 2012; 55-56
• 24 Welte T. Die Sterblichkeit invasiver Pneumokokkenerkrankungen ist hoch – Tun wir alles, um die Letalität zu senken?. Pneumologie 2012; 66: 523-525
• 25 Musher D et al. Antibody persistence 10 years after 1st and 2nd doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of 2nd and 3rd doses in older adults. Human Vaccines 2011; 7: 1-9